Sunday 18 October 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
4.03
0.21
−4.95%
Follow VNDA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 86.26 | 61.83 | 26.15 | 30.56 | 7.56 | 52.26 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 3 | 5 | 4 | 6 | 6 | 4 | 7 | 5 | 6 |
Altman Z-Score |
0.72 | 1.77 | 1.93 | 3.23 | 7.00 | 6.24 | 7.90 | 14.34 | 4.16 | 4.07 |
P/S ratio |
2.41 | 1.40 | 1.35 | 1.65 | 3.24 | 2.88 | 3.84 | 6.89 | 4.23 | 4.64 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 66.45 | 22.54 | 28.63 | 43.76 | 288.01 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
0.13 | 6.91 | 8.09 | 8.85 | 10.00 | 9.29 | 8.75 | 7.10 | (1.25) | (0.35) |
Beneish M-Score |
(3.88) | (2.27) | (2.09) | (2.72) | (2.71) | (2.79) | (1.02) | (1.83) | (2.95) | (2.57) |
P/Operating CF |
(17.67) | (153.29) | (69.50) | 44.49 | 32.76 | 37.05 | 89.06 | 87.14 | 201.35 | (572.96) |
P/B ratio |
1.59 | 0.52 | 0.48 | 0.79 | 1.73 | 1.58 | 2.12 | 4.83 | 5.31 | 5.16 |
Price to Tangible BV |
2.47 | 0.66 | 0.61 | 0.82 | 1.80 | 1.66 | 2.25 | 5.30 | 6.63 | 6.55 |
EV/Sales |
1.20 | (0.47) | (0.63) | (0.15) | 1.67 | 1.45 | 2.52 | 5.55 | 3.36 | 3.67 |
EV/EBITDA |
0.00 | 2.46 | 6.59 | 0.00 | 9.62 | 11.85 | 25.32 | 47.73 | 0.00 | 0.00 |
EV/Operating CF |
(2.38) | 5.90 | (9.49) | (1.22) | 6.99 | 6.93 | 12.46 | 35.77 | (279.60) | (66.21) |
EV/FCF |
(2.35) | 2.04 | 1.07 | (6.20) | 11.61 | 14.37 | 28.72 | 232.28 | (152.03) | (29.44) |
Quick Ratio |
2.19 | 4.22 | 4.82 | 5.47 | 6.25 | 6.03 | 5.69 | 5.40 | 2.29 | 3.21 |
Current Ratio |
2.39 | 4.39 | 4.94 | 5.68 | 6.43 | 6.21 | 5.95 | 5.64 | 2.41 | 3.46 |
Net Debt/EBITDA |
1.84 | 9.81 | 21.08 | (75.10) | (9.06) | (11.76) | (13.26) | (11.45) | 10.00 | 21.09 |
Debt/Assets |
0.83% | 0.48% | 0.00% | 1.39% | 1.69% | 2.16% | 2.57% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.38 | 0.30 | 0.30 | 0.41 | 0.48 | 0.49 | 0.56 | 0.72 | 0.79 | 0.69 |
Operating CF/Net income |
0.50 | 0.83 | 5.10 | 5.10 | 1.94 | 2.22 | 0.40 | 1.19 | 0.13 | 0.45 |
Capex/Depreciation |
(0.10) | (1.68) | 22.63 | 2.95 | (0.12) | (0.59) | 4.92 | (34.51) | (0.65) | (0.12) |
| (50.93%) | (3.49%) | 0.47% | 1.22% | 6.92% | 5.40% | 33.67% | 12.39% | (11.85%) | (13.63%) | |
| (38.51%) | (2.90%) | 0.39% | 1.02% | 5.88% | 4.59% | 28.33% | 9.38% | (7.49%) | (8.51%) | |
ROIC |
(140.15%) | (15.21%) | (5.57%) | 5.72% | 32.07% | 17.55% | 12.81% | 75.22% | 0.00% | 0.00% |
Return on Tangible Assets |
(107.89%) | (5.54%) | 0.72% | 1.46% | 8.15% | 6.72% | 38.71% | 10.06% | (14.85%) | (13.98%) |
Average Days of Receivables |
92.18 | 86.49 | 64.71 | 48.08 | 44.11 | 44.18 | 42.36 | 54.40 | 38.92 | 50.66 |
Research and Development Expense of Revenue |
50.56% | 37.45% | 39.88% | 33.72% | 28.05% | 22.39% | 21.41% | 22.57% | 23.35% | 19.97% |
Selling, General and Administrative Expense of Revenue |
110.11% | 73.66% | 58.60% | 53.65% | 46.17% | 56.62% | 57.11% | 54.76% | 75.02% | 68.34% |
Intangible Assets out of Total Assets |
0.24 | 0.17 | 0.19 | 0.03 | 0.03 | 0.04 | 0.05 | 0.07 | 0.13 | 0.13 |
Share Based Compensation of Revenue |
4.38% | 6.25% | 7.29% | 6.40% | 5.72% | 5.38% | 5.92% | 6.04% | 6.34% | 5.85% |
Graham Net Nets |
0.36 | 1.15 | 1.27 | 0.98 | 0.45 | 0.46 | 0.32 | 0.18 | 0.14 | 0.14 |
Graham Number |
0.00 | 0.00 | 3.35 | 5.02 | 11.08 | 8.98 | 19.43 | 7.80 | 0.00 | 0.00 |
Earnings Yield |
(42.29%) | (6.68%) | 1.16% | 1.62% | 3.82% | 3.27% | 13.22% | 1.91% | (2.18%) | (2.70%) |
Free Cash Flow Yield |
(21.25%) | (16.33%) | (43.66%) | 1.50% | 4.44% | 3.49% | 2.29% | 0.35% | (0.52%) | (2.69%) |
Revenue per Share |
3.67 | 3.42 | 3.36 | 4.51 | 4.84 | 4.56 | 4.28 | 3.79 | 3.69 | 3.36 |
Operating CF per Share |
(1.86) | (0.27) | 0.22 | 0.57 | 1.16 | 0.95 | 0.86 | 0.59 | (0.04) | (0.19) |
Capex per Share |
(0.02) | (0.08) | (1.76) | (0.01) | (0.01) | (0.03) | (0.02) | (0.50) | (0.04) | (0.03) |
Free Cash Flow per Share |
(1.87) | (0.35) | (1.54) | 0.55 | 1.15 | 0.92 | 0.85 | 0.09 | (0.08) | (0.22) |
Cash per Share |
4.48 | 6.44 | 6.77 | 8.27 | 7.79 | 6.76 | 5.87 | 5.06 | 3.21 | 3.25 |
Shareholders Equity per Share |
5.55 | 9.26 | 9.50 | 9.34 | 9.09 | 8.33 | 7.73 | 5.41 | 2.94 | 3.02 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.55 | 9.26 | 9.50 | 9.34 | 9.09 | 8.33 | 7.73 | 5.41 | 2.94 | 3.02 |
Free Cash Flow |
(110.44) | (20.48) | (88.25) | 31.31 | 63.66 | 49.98 | 44.93 | 4.62 | (3.65) | (9.51) |
Working Capital |
202.10 | 338.91 | 345.25 | 427.86 | 403.88 | 343.21 | 294.63 | 246.12 | 99.49 | 123.86 |
Capital Expenditures |
(1.00) | (4.72) | (101.05) | (0.68) | (0.55) | (1.79) | (1.02) | (25.37) | (1.66) | (1.41) |
Net Current Asset Value |
185.50 | 321.23 | 329.42 | 412.24 | 389.44 | 328.96 | 281.33 | 242.42 | 95.82 | 95.13 |
EV/EBIT |
0.00 | 2.29 | 8.70 | 0.00 | 10.64 | 13.18 | 25.09 | 49.34 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.02 | 0.52 | 0.00 | 0.00 | 0.01 | 0.00 | 0.13 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 66.20 | 20.67 | 26.26 | 38.23 | 61.18 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.39 | 1.32 | (2.19) | (0.09) | 1.44 | 0.74 | (0.05) | 0.17 | 0.48 | 2.37 |
Cash ROIC |
(18.56%) | (2.23%) | (9.46%) | 3.12% | 6.72% | 6.00% | 6.11% | 0.87% | (1.33%) | (3.49%) |
Accounts Receivable Turnover |
4.25 | 4.89 | 5.69 | 7.71 | 8.60 | 8.80 | 8.24 | 8.33 | 8.72 | 7.98 |
Accounts Payable Turnover |
0.24 | 0.29 | 0.35 | 0.61 | 0.78 | 0.79 | 1.00 | 0.98 | 0.98 | 1.55 |
Inventory Turnover |
7.29 | 7.34 | 11.60 | 21.89 | 22.24 | 19.31 | 22.95 | 22.36 | 22.05 | 23.84 |
Average Days of Payables |
1,911.10 | 1,260.95 | 948.76 | 684.71 | 490.46 | 492.24 | 411.24 | 384.15 | 415.86 | 239.22 |
Days of Inventory on Hand |
51.82 | 55.68 | 33.48 | 17.95 | 14.60 | 20.00 | 16.99 | 17.69 | 17.18 | 11.51 |
Average Receivables |
50.84 | 40.63 | 33.83 | 32.99 | 31.25 | 28.20 | 27.57 | 23.19 | 18.93 | 18.30 |
Average Payables |
53.69 | 38.77 | 42.01 | 39.99 | 32.97 | 29.55 | 24.59 | 20.96 | 18.27 | 15.98 |
Average Inventory |
1.79 | 1.54 | 1.28 | 1.11 | 1.15 | 1.21 | 1.07 | 0.92 | 0.81 | 1.04 |
Average Assets |
572.58 | 652.32 | 641.34 | 614.02 | 563.62 | 508.60 | 407.94 | 268.78 | 207.90 | 211.71 |
Average Common Equity |
432.87 | 541.73 | 536.05 | 516.06 | 479.10 | 432.11 | 343.18 | 203.40 | 131.36 | 132.18 |
Columns are period end dates